|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
4 September 2023 |
|
Main ID: |
NCT03183661 |
|
Date of registration:
|
08/06/2017 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
A Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in ALLO-ASC-CD-101 Clinical Trial
|
|
Scientific title:
|
Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in the Subjects With Crohn´s Disease(ALLO-ASC-CD-101) |
|
Date of first enrolment:
|
November 16, 2016 |
|
Target sample size:
|
9 |
|
Recruitment status: |
Recruiting |
|
URL:
|
https://clinicaltrials.gov/ct2/show/NCT03183661 |
|
Study type:
|
Observational |
|
Study design:
|
|
|
Phase:
|
|
|
|
Countries of recruitment
|
|
Korea, Republic of
| | | | | | | |
|
Contacts
|
|
Name:
|
Joosung Kim, MD, Ph.D. |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
jooskim@snu.ac.kr, |
|
Affiliation:
|
|
|
|
Name:
|
Young Ho Kim, Ph D |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Samsung Medical Center |
|
|
Name:
|
Jae Hee Cheon, Ph D |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Yonsei University |
|
|
Name:
|
Jae Hee Cheon, Ph D |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
GENIUSHEE@yuhs.ac |
|
Affiliation:
|
|
|
|
Name:
|
Joo Sung Kim, Ph D |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Seoul National University Hospital |
| |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
1. Subjects who are injected with ALLO-ASC-CD in phase 1 clinical trial of
ALLO-ASC-CD-101.
2. Subjects who are able to give written informed consent prior to study start and to
comply with the study requirements.
Exclusion Criteria:
1. Subjects who are considered not suitable for the study by the principal investigator.
Age minimum:
18 Years
Age maximum:
65 Years
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Crohn Disease
|
|
Intervention(s)
|
|
Biological: ALLO-ASC-CD
|
|
Primary Outcome(s)
|
|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
[Time Frame: up to 36 months]
|
|
Secondary ID(s)
|
|
ALLO-ASC-CD-102
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|